Nigerian drugmaker Emzor Pharmaceutical Industries Limited has partnered with Indian drugmaker Mangalam Drugs and Organics Limited in an active pharmaceutical ingredients (APIs) manufacturing technology transfer and licensing deal.
The deal will enable it locally manufacture APIs* for malaria treatment.
Emzor is a leading pan-African manufacturer and distributor of medical supplies, world-class medicine and surgical equipment.
The latest deal covers a co-development basis for its manufacturing four APIs critical for treating malaria, including artemether, lumefantrine, sulfadoxine and pyrimethamine.
Malaria is a deadly disease that is common in Sub-Saharan Africa. It is expensive to treat, which is one of the reasons it claims hundreds of thousands of lives each year.
Commenting on the partnership, Emzor Managing Director Stella Okol noted that the Mangalam deal provides Emzor with an opportunity to become a leader in the global fight against malaria, lending its tireless commitment to bring affordable drugs for all.
“Most importantly, we begin the journey to self-reliance and sustainability of the pharma sector in Africa and enhance our ability to respond in times of global emergencies,” Okoli said.
Mangalam will provide in-house developed technology for manufacturing antimalarial APIs, consultation and relevant designs for setting up a world-class API manufacturing facility compliant with World Health Organization standards in Nigeria.
Emzor Pharmaceutical Industries Limited.
Emzor is a privately-held Nigerian pharma manufacturing group founded in 1984 by Okoli.
Okoli, who has received numerous local and international awards, currently serves as group managing director.
Mangalam Drugs and Organics Limited
Mangalam is reputed globally as a single-stop destination for frontline anti-malaria treatment. The business, which is listed on the Indian bourse, was founded in 1977 in VAPI – Gujarat (India), where it began manufacturing APIs.
*APIs are any substance or combination of substances used in a finished pharmaceutical product (FPP) intended to directly affect the diagnosis, cure, mitigation, treatment or prevention of disease in human beings.